Pfizer's French subsidiary expects further job cuts due to the expiration, in May 2012, of the anti-cholesterol patent Tahor (atorvastatin – Torvast, Lipitor, Totalip, Xarator). According to the Ministry of Health, this measure would affect around 1,500 hospital ISFs, out of a total of 4,000 people. In 2009, Pfizer fired around 700 people in France, 600 of whom were ISF. Tahor's sales in 2010 reached €423 million, an increase of 3.2% compared to 2009.
(Les Echos Pag.21 – 14/09/2011, Les Echos online – 14/09/2011)
